Endovascular Thrombectomy

Stroke. 2018 Nov;49(11):2783-2785. doi: 10.1161/STROKEAHA.118.022919.

Abstract

Background and Purpose- This study aimed to explore safety of tirofiban in endovascular treatment of acute ischemic stroke. Methods- Two hundred eighteen ischemic stroke patients receiving endovascular thrombectomy were prospectively recruited, with 94 treated with intra-arterial tirofiban and 124 were not. The 2 groups were compared in terms of symptomatic intracranial hemorrhage (ICH) and fatal ICH rate by the χ2 test and logistic regression. Results- Patients treated with tirofiban compared with those without tirofiban had significantly higher rate of symptomatic ICH (14.6% versus 5.7%; P=0.027) and fatal ICH (8.8% versus 1.6%; P=0.014). Tirofiban-treated patients had increased odds of symptomatic ICH by 2.9-fold (95% CI, 1.1-7.5), and odds of fatal ICH increased by 5.9-fold (95% CI, 1.2-28.4). Conclusions- Tirofiban treatment increases risk of major ICH after endovascular thrombectomy for acute ischemic stroke in this nonrandomized study.

Keywords: hemorrhage; intracranial hemorrhage; risk; stroke; thrombectomy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Endovascular Procedures / methods*
  • Female
  • Fibrinolytic Agents / therapeutic use*
  • Humans
  • Injections, Intra-Arterial
  • Intracranial Hemorrhages / epidemiology*
  • Intracranial Hemorrhages / mortality
  • Logistic Models
  • Male
  • Middle Aged
  • Postoperative Hemorrhage / epidemiology*
  • Postoperative Hemorrhage / mortality
  • Prospective Studies
  • Stroke / therapy*
  • Thrombectomy / methods*
  • Tirofiban / therapeutic use*

Substances

  • Fibrinolytic Agents
  • Tirofiban